Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer

• Published in: Cancer cell Vol. 41; no. 10; pp. 1749 - 1762.e6
• Main Authors: Chen, Kezhong, Yang, Fan, Shen, Haifeng, Wang, Chenyang, Li, Xi, Chervova, Olga, Wu, Shuailai, Qiu, Fujun, Peng, Di, Zhu, Xin, Chuai, Shannon, Beck, Stephan, Kanu, Nnennaya, Carbone, David, Zhang, Zhihong, Wang, Jun
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 09-10-2023
• Subjects: Circulating tumor DNA; Liquid biopsy; Minimal residual disease; Non-canonical variant; Non-small cell lung cancer; Surveillance; Tumor-informed; Non-canonical variant; Surveillance; Non-small cell lung cancer; Minimal residual disease; Liquid biopsy; Circulating tumor DNA; Tumor-informed
• ISSN: 1535-6108; 1878-3686
• DOI: 10.1016/j.ccell.2023.08.010

We report a personalized tumor-informed technology, Patient-specific pROgnostic and Potential tHErapeutic marker Tracking (PROPHET) using deep sequencing of 50 patient-specific variants to detect molecular residual disease (MRD) with a limit of detection of 0.004%. PROPHET and state-of-the-art fixed-panel assays were applied to 760 plasma samples from 181 prospectively enrolled early stage non-small cell lung cancer patients. PROPHET shows higher sensitivity of 45% at baseline with circulating tumor DNA (ctDNA). It outperforms fixed-panel assays in prognostic analysis and demonstrates a median lead-time of 299 days to radiologically confirmed recurrence. Personalized non-canonical variants account for 98.2% with prognostic effects similar to canonical variants. The proposed tumor-node-metastasis-blood (TNMB) classification surpasses TNM staging for prognostic prediction at the decision point of adjuvant treatment. PROPHET shows potential to evaluate the effect of adjuvant therapy and serve as an arbiter of the equivocal radiological diagnosis. These findings highlight the potential advantages of personalized cancer techniques in MRD detection.
[Display omitted]
•PROPHET outperforms fixed-panel MRD assays in head-to-head comparison in NSCLC•TNMB stage, integrating landmark ctDNA MRD and TNM, improves prognosis prediction•PROPHET illustrates a median lead time of 299 days to radiological recurrence•Post-relapse ctDNA status facilitates decision on later lines of treatment
Chen et al. introduce personalized Patient-specific pROgnostic and Potential tHErapeutic marker Tracking (PROPHET) for detecting molecular residual disease (MRD) in NSCLC, featuring a notably low limit of detection (LOD). It exhibits elevated sensitivity and extended lead time than radiologically confirmed recurrence. It also facilitates prognostic accuracy and postoperative treatment evaluation.